Global Uterine Cancer Drugs Market – Industry Trends and Forecast to 2030

Pharmaceutical
Published Report
Nov 2023
Global
350 Pages
No of Tables: 733
No of Figures: 48

Global Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.

Uterine Cancer Drugs Market Analysis and Insights

The global uterine cancer drug market is a vital segment within the broader oncology pharmaceutical industry, reflecting the increasing prevalence of uterine cancer cases worldwide. Uterine cancer ranks among the most common gynecological malignancies, with an incidence rate that has been steadily rising over the years. Several factors contribute to this trend, including an aging population, the obesity epidemic, and improved diagnostic capabilities, leading to earlier detection. As a result, the market for uterine cancer drugs continues to expand as pharmaceutical companies develop innovative treatments to address the needs of patients facing this challenging disease.

Key drivers of the global uterine cancer drug market include advancements in R&D, a growing emphasis on precision medicine, and an evolving understanding of the molecular mechanisms driving the market.

However, the market faces challenges such as the high cost associated with treatment cost, lack of skilled personnel, and complex regulatory requirements.

The global uterine cancer drugs market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.5% in the forecast period of 2023 to 2030 and is expected to reach USD 4,269,049.34 thousand by 2030 from USD 2,412,036.20 thousand in 2022.

The global uterine cancer drugs market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.

Report Metric	Details
Forecast Period	2023 to 2030
Base Year	2022
Historic Years	2021 (Customizable to 2015-2020)
Quantitative Units	Revenue in USD Thousand
Segments Covered	Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
Countries Covered	U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa
Market Players Covered	Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus, and Getwell Oncology among others.

Global Uterine Cancer Drugs Market Definition

Uterine cancer drugs comprise a class of pharmaceutical drugs and therapies designed specifically to treat and manage uterine cancer, a malignancy originating in the endometrium, the inner lining of the uterus. These drugs play a critical role in the comprehensive treatment and care of individuals diagnosed with uterine cancer. Their primary objectives are to target, suppress, or eliminate cancerous cells within the uterus, thereby slowing or halting the progression of the disease and reducing associated symptoms, such as abnormal uterine bleeding, pelvic pain, and discomfort.

Global Uterine Cancer Drugs Market Dynamics

Drivers

Rising Incidence of Uterine Cancer Worldwide

In recent years, the world has witnessed a notable surge in the prevalence of uterine cancer, emerging as a significant global health concern. The rising incidence of uterine cancer worldwide is a complex and multifaceted issue, influenced by a combination of genetic, lifestyle, environmental, and healthcare factors.

For instance,

In March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), uterine cancer is the fourth most common cancer for women in the U.S., worldwide an estimated 417,367 people were diagnosed with uterine cancer in 2020

Thus, the rising incidence of uterine cancer worldwide is driving the market growth.

Growing Advancements in Targeted Therapy for Uterine Cancer

Advancements in targeted therapy for uterine cancer have shown promise in improving treatment outcomes, reducing side effects, and enhancing the quality of life for patients. Targeted therapy is a type of cancer treatment that focuses on specific molecules or pathways involved in the growth and spread of cancer cells rather than broadly affecting rapidly dividing cells, as in traditional chemotherapy.

Targeted therapies are drugs designed to target particular changes in cancer cells. They can be helpful for high risk or advanced uterine cancer.

For instance,

Lenvatinib (Lenvima) is a kinase inhibitor. It stops tumors from forming new blood vessels. It also targets proteins in cancer cells that help them grow. A doctor may use Lenvima in combination with Keytruda. It comes as an oral capsule you take every day.

Thus, growing advancements in targeted therapy for uterine cancer is driving the market growth.

Opportunity

Advancements in Genomic Profiling and Biomarker Discovery

Advancements in genomic profiling and biomarker discovery have significantly impacted uterine cancer treatment, offering a more targeted and personalized approach to managing the disease. Uterine cancer encompasses a range of subtypes, and these advancements have helped identify genetic variations and molecular characteristics specific to each subtype, allowing for more effective treatment strategies.

In conclusion, advancements in genomic profiling and biomarker discovery have transformed the landscape of uterine cancer treatment. These developments have led to a better understanding of the genetic and molecular characteristics of uterine cancer subtypes, more targeted treatment options, and the potential for earlier detection. It holds promise for further improving patient outcomes and expanding the array of therapeutic options available to individuals with uterine cancer as research continues to evolve in this field. Thus, advancements in genomic profiling and biomarker discovery is expected to act as an opportunity for the market growth.

Challenges/Restraints

High Cost of Uterine Cancer Treatment

Uterine cancer often requires multimodal treatment, which can include surgery, radiation therapy, chemotherapy, targeted therapy, and hormone therapy. The combined expenses of these various treatment modalities, along with the associated hospital stays, consultations, and follow-up visits, can significantly escalate the overall cost of treatment. Patients with uterine cancer may require hospitalization for surgeries, chemotherapy, or radiation therapy, leading to substantial costs associated with hospital stays, operating room expenses, and inpatient care.

Thus, the high cost of uterine cancer treatment is hampering the market growth.

Regulatory Hurdles in the Market

The regulatory hurdles in the market are critical factors that shape the development, approval, and accessibility of new treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, are responsible for ensuring the safety, efficacy, and quality of drugs. These agencies set strict standards and guidelines that companies must adhere to during the drug development process.

In conclusion, the regulatory hurdles in the market are multifaceted and often prolonged.

Thus, regulatory hurdles in the market is expected to act as challenge for the market growth.

Recent Developments

In October 2023, Merck and Co., Inc. introduced effects from the Phase three KEYNOTE-A39 trial (additionally referred to as EV-302), which turned into carried out in collaboration with Seagen and Astellas, comparing KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, as compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in sufferers with formerly untreated domestically superior or metastatic urothelial carcinoma. This will help the company to expand the application of its brand KEYTRUDA
In December 2022, Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. This collaboration will help to expand sanofi’s oncology portfolio in the global market

Global Uterine Cancer Drugs Market Scope

The global uterine cancer drugs market is categorized into five notable segments based on cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Cancer Type

Endometrial Cancer
Uterine Sarcoma

On the basis of cancer type, the market is segmented into endometrial cancer and uterine sarcoma.

Treatment Type

Chemotherapy
Immunotherapy
Hormone Therapy
Targeted Therapy
Others

On the basis of treatment type, the market is segmented into chemotherapy, immunotherapy, hormone therapy, targeted therapy, and others.

Drug Type

Generics
Branded

On the basis of drug type, the market is segmented into generics and branded.

Age Group

Geriatric
Adults

On the basis of age group, the market is segmented into geriatric and adults.

Route of Administration

Parenteral
Oral

On the basis of route of administration, the market is segmented into parenteral and oral.

End-User

Hospitals
Cancer Centers
Specialty Clinics
Others

On the basis of end-user, the market is segmented into hospitals, cancer centers, specialty clinics, and others.

Distribution Channel

Direct Tender
Retail Sales
Others

On the basis of distribution channel, the global uterine cancer drug market is segmented into direct tender, retail sales, and others.

Regional Analysis/Insights: Global Uterine Cancer Drugs Market

The global uterine cancer drugs market is categorized into seven notable segments such as cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.

The countries covered in this market report U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa.

The U.S. is expected to dominate the North America region due to the rise in technological advancement in uterine cancer drugs products market. Germany is expected to dominate the Europe region due to the strong presence of key players. China is expected to dominate the Asia-Pacific region due to the mass production of uterine cancer drugs based products and increasing demand from emerging markets and expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market

Global uterine cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Global Uterine Cancer Drugs market.

Some of the major players operating in the global uterine cancer drugs market are Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus, and Getwell Oncology among others.

SKU-50353

TABLE 1 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND)

TABLE 2 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 GLOBAL IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 10 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 GLOBAL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 GLOBAL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 GLOBAL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 GLOBAL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 18 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 20 GLOBAL GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND)

TABLE 24 GLOBAL GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 GLOBAL ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 GLOBAL PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 GLOBAL ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND)

TABLE 30 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 32 GLOBAL CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 GLOBAL SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND)

TABLE 36 GLOBAL DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 46 NORTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 47 NORTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 NORTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 49 NORTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 50 NORTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 51 NORTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 NORTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 53 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 NORTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 55 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 56 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 57 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 58 NORTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 60 NORTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 U.S. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 U.S. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 U.S. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 U.S. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 66 U.S. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 67 U.S. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 68 U.S. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 69 U.S. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 70 U.S. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 U.S. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 72 U.S. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 U.S. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 74 U.S. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 75 U.S. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 76 U.S. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 77 U.S. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 U.S. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 79 U.S. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 CANADA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 CANADA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 83 CANADA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 CANADA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 85 CANADA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 CANADA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 87 CANADA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 88 CANADA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 89 CANADA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 CANADA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 91 CANADA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 CANADA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 93 CANADA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 94 CANADA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 CANADA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 96 CANADA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 CANADA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 98 CANADA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 99 MEXICO UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 MEXICO UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 MEXICO UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 MEXICO CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 104 MEXICO HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 105 MEXICO PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 106 MEXICO AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 107 MEXICO LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 108 MEXICO TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 MEXICO MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 110 MEXICO UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 MEXICO BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 112 MEXICO UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 113 MEXICO UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 114 MEXICO UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 115 MEXICO HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 MEXICO UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 117 MEXICO RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 119 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 121 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 124 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 126 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 127 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 128 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 130 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 131 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 132 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 133 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 134 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 135 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 137 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 142 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 143 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 145 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 146 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 147 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 149 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 151 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 152 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 153 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 154 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 156 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 158 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 159 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 162 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 163 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 164 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 165 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 166 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 168 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 169 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 170 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 171 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 172 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 173 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 174 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 181 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 183 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 184 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 185 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 187 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 189 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 190 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 191 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 192 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 194 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 195 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 196 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 200 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 201 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 202 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 203 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 204 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 206 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 207 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 208 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 209 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 210 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 211 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 213 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 217 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 219 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 221 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 222 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 223 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 224 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 225 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 227 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 228 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 229 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 230 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 232 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 233 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 236 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 237 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 238 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 239 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 240 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 241 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 242 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 244 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 246 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 247 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 248 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 249 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 251 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 253 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 254 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 255 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 256 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 257 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 258 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 259 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 260 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 261 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 263 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 265 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 266 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 267 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 268 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 269 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 270 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 271 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 272 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 273 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 274 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 275 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 276 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 278 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 279 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 280 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 282 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 284 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 285 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 287 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 288 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 289 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 290 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 291 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 292 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 293 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 294 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 295 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 296 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 297 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 298 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 299 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 300 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 301 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 302 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 303 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 304 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 305 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 306 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 307 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 308 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 310 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 314 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 315 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 316 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 317 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 318 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 319 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 320 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 321 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 322 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 323 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 324 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 325 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 326 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 327 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 328 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 329 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 330 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 331 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 332 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 333 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 334 ASIA-PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 335 ASIA-PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 336 ASIA-PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 337 ASIA-PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 338 ASIA-PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 339 ASIA-PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 340 ASIA-PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 341 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 342 ASIA-PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 343 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 344 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 345 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 346 ASIA-PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 347 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 348 ASIA-PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 349 CHINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 350 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 351 CHINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 352 CHINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 CHINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 354 CHINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 355 CHINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 356 CHINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 357 CHINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 358 CHINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 CHINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 360 CHINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 361 CHINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 362 CHINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 363 CHINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 364 CHINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 365 CHINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 366 CHINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 367 CHINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 368 JAPAN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 369 JAPAN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 370 JAPAN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 371 JAPAN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 372 JAPAN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 373 JAPAN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 374 JAPAN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 375 JAPAN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 376 JAPAN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 377 JAPAN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 378 JAPAN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 379 JAPAN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 JAPAN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 381 JAPAN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 382 JAPAN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 383 JAPAN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 384 JAPAN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 385 JAPAN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 386 JAPAN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 387 INDIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 388 INDIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 389 INDIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 390 INDIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 391 INDIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 392 INDIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 393 INDIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 394 INDIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 395 INDIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 396 INDIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 397 INDIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 398 INDIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 399 INDIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 400 INDIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 401 INDIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 402 INDIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 403 INDIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 404 INDIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 405 INDIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 406 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 407 AUSTRALIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 408 AUSTRALIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 409 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 AUSTRALIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 411 AUSTRALIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 AUSTRALIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 413 AUSTRALIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 414 AUSTRALIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 415 AUSTRALIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 416 AUSTRALIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 417 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 418 AUSTRALIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 419 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 420 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 421 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 422 AUSTRALIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 423 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 424 AUSTRALIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 425 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 426 SOUTH KOREA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 427 SOUTH KOREA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 428 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 429 SOUTH KOREA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 430 SOUTH KOREA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 431 SOUTH KOREA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 432 SOUTH KOREA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 433 SOUTH KOREA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 434 SOUTH KOREA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 435 SOUTH KOREA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 436 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 437 SOUTH KOREA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 438 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 439 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 440 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 441 SOUTH KOREA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 442 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 443 SOUTH KOREA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 444 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 NEW ZEALAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 NEW ZEALAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 447 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 448 NEW ZEALAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 449 NEW ZEALAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 450 NEW ZEALAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 451 NEW ZEALAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 452 NEW ZEALAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 453 NEW ZEALAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 454 NEW ZEALAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 455 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 456 NEW ZEALAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 457 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 458 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 459 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 460 NEW ZEALAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 461 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 462 NEW ZEALAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 463 SINGAPORE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 464 SINGAPORE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 465 SINGAPORE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 466 SINGAPORE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 467 SINGAPORE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 468 SINGAPORE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 469 SINGAPORE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 470 SINGAPORE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 471 SINGAPORE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 472 SINGAPORE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 473 SINGAPORE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 474 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 475 SINGAPORE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 476 SINGAPORE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 477 SINGAPORE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 478 SINGAPORE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 479 SINGAPORE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 480 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 481 SINGAPORE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 482 THAILAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 483 THAILAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 484 THAILAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 485 THAILAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 486 THAILAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 487 THAILAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 488 THAILAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 489 THAILAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 490 THAILAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 491 THAILAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 THAILAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 493 THAILAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 494 THAILAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 495 THAILAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 496 THAILAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 497 THAILAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 498 THAILAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 499 THAILAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 500 THAILAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 501 MALAYSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 502 MALAYSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 503 MALAYSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 504 MALAYSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 505 MALAYSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 506 MALAYSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 507 MALAYSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 508 MALAYSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 509 MALAYSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 510 MALAYSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 511 MALAYSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 512 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 513 MALAYSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 514 MALAYSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 515 MALAYSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 516 MALAYSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 517 MALAYSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 518 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 519 MALAYSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 520 INDONESIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 521 INDONESIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 522 INDONESIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 523 INDONESIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 524 INDONESIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 525 INDONESIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 526 INDONESIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 527 INDONESIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 528 INDONESIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 529 INDONESIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 530 INDONESIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 531 INDONESIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 532 INDONESIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 533 INDONESIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 534 INDONESIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 535 INDONESIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 536 INDONESIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 537 INDONESIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 538 INDONESIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 539 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 540 PHILIPPINES ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 541 PHILIPPINES UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 542 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 543 PHILIPPINES CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 544 PHILIPPINES HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 545 PHILIPPINES PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 546 PHILIPPINES AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 547 PHILIPPINES LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 548 PHILIPPINES TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 549 PHILIPPINES MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 550 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 551 PHILIPPINES BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 552 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 553 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 554 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 555 PHILIPPINES HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 556 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 557 PHILIPPINES RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 558 REST OF ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 559 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 560 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 561 SOUTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 562 SOUTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 563 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 564 SOUTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 565 SOUTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 566 SOUTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 567 SOUTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 568 SOUTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 569 SOUTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 570 SOUTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 571 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 572 SOUTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 573 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 574 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 575 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 576 SOUTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 577 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 578 SOUTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 579 BRAZIL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 580 BRAZIL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 581 BRAZIL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 582 BRAZIL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 583 BRAZIL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 584 BRAZIL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 585 BRAZIL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 586 BRAZIL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 587 BRAZIL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 588 BRAZIL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 589 BRAZIL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 590 BRAZIL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 591 BRAZIL BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 592 BRAZIL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 593 BRAZIL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 594 BRAZIL UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 595 BRAZIL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 596 BRAZIL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 597 BRAZIL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 598 ARGENTINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 599 ARGENTINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 600 ARGENTINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 601 ARGENTINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 602 ARGENTINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 603 ARGENTINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 604 ARGENTINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 605 ARGENTINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 606 ARGENTINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 607 ARGENTINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 608 ARGENTINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 609 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 610 ARGENTINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 611 ARGENTINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 612 ARGENTINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 613 ARGENTINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 614 ARGENTINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 615 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 616 ARGENTINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 617 REST OF SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 618 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 619 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 620 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 621 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 622 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 623 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 624 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 625 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 626 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 627 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 628 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 629 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 630 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 631 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 632 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 633 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 634 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 635 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 638 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 639 SAUDI ARABIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 640 SAUDI ARABIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 641 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 642 SAUDI ARABIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 643 SAUDI ARABIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 644 SAUDI ARABIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 645 SAUDI ARABIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 646 SAUDI ARABIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 647 SAUDI ARABIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 648 SAUDI ARABIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 649 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 650 SAUDI ARABIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 651 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 652 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 653 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 654 SAUDI ARABIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 655 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 656 SAUDI ARABIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 657 U.A.E. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 658 U.A.E. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 659 U.A.E. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 660 U.A.E. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 661 U.A.E. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 662 U.A.E. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 663 U.A.E. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 664 U.A.E. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 665 U.A.E. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 666 U.A.E. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 667 U.A.E. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 668 U.A.E. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 669 U.A.E. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 670 U.A.E. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 671 U.A.E. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 672 U.A.E. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 673 U.A.E. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 674 U.A.E. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 675 U.A.E. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 676 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 677 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 678 SOUTH AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 679 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 680 SOUTH AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 681 SOUTH AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 682 SOUTH AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 683 SOUTH AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 684 SOUTH AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 685 SOUTH AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 686 SOUTH AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 687 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 688 SOUTH AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 689 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 690 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 691 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 692 SOUTH AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 693 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 694 SOUTH AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 695 EGYPT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 696 EGYPT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 697 EGYPT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 698 EGYPT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 699 EGYPT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 700 EGYPT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 701 EGYPT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 702 EGYPT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 703 EGYPT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 704 EGYPT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 705 EGYPT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 706 EGYPT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 707 EGYPT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 708 GYPT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 709 EGYPT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 710 EGYPT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 711 EGYPT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 712 EGYPT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 713 EGYPT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 714 KUWAIT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 715 KUWAIT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 716 KUWAIT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 717 KUWAIT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 718 KUWAIT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 719 KUWAIT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 720 KUWAIT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 721 KUWAIT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 722 KUWAIT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 723 KUWAIT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 724 KUWAIT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 725 KUWAIT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 726 KUWAIT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 727 KUWAIT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 728 KUWAIT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 729 KUWAIT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 730 KUWAIT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 731 KUWAIT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 732 KUWAIT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 733 REST OF MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

How big is the uterine cancer drug market?

The uterine cancer drug market size will be worth USD 4,269,049.34 thousand by 2030.

What is the growth rate of the uterine cancer drug market?

The growth rate of the uterine cancer drug market is 8.5% in the forecast period by 2030.

What are the growth drivers of the uterine cancer drug market?

The rising incidence of uterine cancer worldwide & growing advancements in targeted therapy for uterine cancer are the growth drivers of the uterine cancer drug market.

What are the factors on which the uterine cancer drug market research is based on?

Cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel are the factors on which the uterine cancer drug market research is based.

Which are the major companies in the uterine cancer drug market?

Major companies in the uterine cancer drug market are Baxter, Accord BioPharma, Inc., Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., Virtus, and Getwell Oncology among others.

BROWSE RELATED Press Release

Growing Advancements in Targeted Therapy for Uterine Cancer is Driving the Growth of the Market

Growing Advancements in Targeted Therapy for Uterine Cancer is Driving the Growth of the Europe Uterine Cancer Drugs Market

Free Sample Report

CHOOSE LICENCE TYPE

Enterprise User 7000.00
Single User 4800.00
DBMR Factbook 3000.00
DBMR Prime 8000.00
DBMR Supreme 12000.00

Buy Now

Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report

Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Pharmaceutical

Global Uterine Cancer Drugs Market – Industry Trends and Forecast to 2030

Uterine Cancer Drugs Market Analysis and Insights

Global Uterine Cancer Drugs Market Definition

Global Uterine Cancer Drugs Market Dynamics

Global Uterine Cancer Drugs Market Scope

Regional Analysis/Insights: Global Uterine Cancer Drugs Market

Competitive Landscape and Share Analysis: Global Uterine Cancer Drugs Market

Please fill in the below form for Infographics

Research Methodology:

Please fill in the below form for Research Methodology

Customization Available:

Please fill in the below form for Available Customization

FREQUENTLY ASK QUESTIONS

BROWSE RELATED REPORTS

BROWSE RELATED Press Release

CHOOSE LICENCE TYPE

Why Choose Us

Industry Coverage

Regional Coverage

Technology Coverage

Goal Oriented Solutions

Unparallel Analyst Support

Client Testimonials

David Manning - Thermo Fisher Scientific

Manager - Market Analytics,

Business Development Manager,

Business Intelligence and Analytics,

Competition Analyst,

Marketing Director,

COO,

Marketing Director,

Product manager,

Investor relations,

Market Analyst,

Andrew - Senior Global Marketing Manager,

Amarildo - Manager, Global Strategic Alignment

Tor Hammer

Tommaso Finocchiaro

Yuki Kopyl (Asian Business Development Department)

Share Your Experience With Us

Share Your
Experience With Us